Literature DB >> 23778024

Individualized correction of neuron-specific enolase (NSE) measurement in hemolyzed serum samples.

Nicole V Tolan1, Noemi Vidal-Folch, Alicia Algeciras-Schimnich, Ravinder J Singh, Stefan K G Grebe.   

Abstract

BACKGROUND: Accuracy of serum neuron-specific enolase (NSE) measurement is paramount, particularly in the context of neurological outcome prognostication. However, NSE measurements are compromised by even slight hemolysis, as it is abundant in red blood cells (RBCs). We derived and validated an individualized hemolysis correction equation in an attempt to reduce the current rejection rate of 14% at our institution.
METHODS: Intracellular NSE was measured in RBC lysates to determine concentration variability. A correction equation was derived, accounting for both RBC-derived NSE false-elevation and hemoglobin-derived signal quenching. The performance of this individualized correction was evaluated in intentionally hemolyzed samples and accuracy was compared to a generalized correction.
RESULTS: Significant inter-individual variability of RBC NSE was observed, with an almost two-fold range (15.7-28.5 ng NSE/mg Hb, p<0.001); intra-individual variability was insignificant. The individualized hemolysis correction equation derived: NSE(corr)=NSE(meas)-(Hb(serum))(NSE(RBCs/Hb))+0.0844(Hb(serum))+1.1 corrected 95% of the intentionally hemolyzed samples to within ±5 ng/ml of corresponding baseline NSE concentrations, compared to 74% using a generalized formula.
CONCLUSIONS: The individualized hemolysis correction provides increased accuracy in the estimation of true serum NSE concentrations for hemolyzed samples, compared to a generalized approach, by accounting for inter-individual RBC NSE variability. Incorporating this correction should reduce sample rejection rates and overall health care costs.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Individualized hemolysis correction; Ischemic brain injury; Neurological prognosis; Neuron-specific enolase; Therapeutic hypothermia

Mesh:

Substances:

Year:  2013        PMID: 23778024     DOI: 10.1016/j.cca.2013.06.009

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  14 in total

Review 1.  Current status of fluid biomarkers in mild traumatic brain injury.

Authors:  Jacqueline R Kulbe; James W Geddes
Journal:  Exp Neurol       Date:  2015-05-14       Impact factor: 5.330

2.  Individualized correction of insulin measurement in hemolyzed serum samples.

Authors:  Zhi-Qi Wu; Ju Lu; Huanhuan Chen; Wensen Chen; Hua-Guo Xu
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

3.  In vitro selection of DNA aptamers for the development of chemiluminescence aptasensor for neuron-specific enolase (NSE) detection.

Authors:  Yue Zheng; Yunwang Zhao; Ya Di; Lei He; Shiqi Liao; Dongdong Li; Xiaofei Liu
Journal:  RSC Adv       Date:  2019-05-17       Impact factor: 4.036

4.  A correction formula for neuron-specific enolase measurement in hemolyzed neonatal serum samples.

Authors:  Qiang Wang; Guangrong Wang; Xiaolan Lu; Xiaolan Guo; Qin Du; Fang Lin; Quming Fan; Guoyuan Zhang; Dongsheng Wang
Journal:  Biomed Rep       Date:  2018-03-21

5.  Reducing acetylated tau is neuroprotective in brain injury.

Authors:  Min-Kyoo Shin; Edwin Vázquez-Rosa; Yeojung Koh; Matasha Dhar; Kalyani Chaubey; Coral J Cintrón-Pérez; Sarah Barker; Emiko Miller; Kathryn Franke; Maria F Noterman; Divya Seth; Rachael S Allen; Cara T Motz; Sriganesh Ramachandra Rao; Lara A Skelton; Machelle T Pardue; Steven J Fliesler; Chao Wang; Tara E Tracy; Li Gan; Daniel J Liebl; Jude P J Savarraj; Glenda L Torres; Hilda Ahnstedt; Louise D McCullough; Ryan S Kitagawa; H Alex Choi; Pengyue Zhang; Yuan Hou; Chien-Wei Chiang; Lang Li; Francisco Ortiz; Jessica A Kilgore; Noelle S Williams; Victoria C Whitehair; Tamar Gefen; Margaret E Flanagan; Jonathan S Stamler; Mukesh K Jain; Allison Kraus; Feixiong Cheng; James D Reynolds; Andrew A Pieper
Journal:  Cell       Date:  2021-04-13       Impact factor: 41.582

Review 6.  Biomarkers of Traumatic Brain Injury: Temporal Changes in Body Fluids.

Authors:  Harel Adrian; Kvist Mårten; Nuutinen Salla; Välimaa Lasse
Journal:  eNeuro       Date:  2016-12-21

7.  Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma.

Authors:  Daniel G Weber; Katarzyna Gawrych; Swaantje Casjens; Alexander Brik; Martin Lehnert; Dirk Taeger; Beate Pesch; Jens Kollmeier; Torsten T Bauer; Georg Johnen; Thomas Brüning
Journal:  Dis Markers       Date:  2017-02-21       Impact factor: 3.434

8.  Nilotinib - Differentiating the Hope from the Hype.

Authors:  Richard K Wyse; Patrik Brundin; Todd B Sherer
Journal:  J Parkinsons Dis       Date:  2016-07-12       Impact factor: 5.568

Review 9.  A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury.

Authors:  Eric Peter Thelin; David W Nelson; Bo-Michael Bellander
Journal:  Acta Neurochir (Wien)       Date:  2016-12-12       Impact factor: 2.216

10.  Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity.

Authors:  Eric Peter Thelin; Emma Jeppsson; Arvid Frostell; Mikael Svensson; Stefania Mondello; Bo-Michael Bellander; David W Nelson
Journal:  Crit Care       Date:  2016-09-08       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.